Imvax
Imvax is a clinical-stage biotechnology company focused on the development of patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with unmet medical needs.
4
Funding Rounds
$192.4m
Money raised
| Name | Phone | Social networks | |
|---|---|---|---|
| D. Cr*** Ho**** | - | - | - |
| Da*** An***** (e************ | - | - | - |
| Ar**** W. Ho** | - | - | - |
| Pe*** Co** | - | - | - |
Funding
Funding series
Funding Series Analysis
The company Imvax has raised a total of $80m in funding over 4 rounds.
Key Insights:
- Imvax , September 2019: $40m
- Imvax Series B: $25m
- Imvax Series A: $15m
- Imvax, Inc. funding round, July 2020: $112.37m
Imvax , September 2019
$40m
Imvax Series B
$25m
Imvax Series A
$15m
Imvax, Inc. funding round, July 2020
$112.37m
Industries
Imvax is active in the following industries:
- Engineering
- Therapeutics
- Biomedical engineering
- Biopharmaceutical
- Technology
- Biotechnology
- Biology
- Healthcare
- Regenerative medicine
- Cell therapy
- Immunotherapy